BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 21926427)

  • 1. CYP2C19 genotype predicts steady state escitalopram concentration in GENDEP.
    Huezo-Diaz P; Perroud N; Spencer EP; Smith R; Sim S; Virding S; Uher R; Gunasinghe C; Gray J; Campbell D; Hauser J; Maier W; Marusic A; Rietschel M; Perez J; Giovannini C; Mors O; Mendlewicz J; McGuffin P; Farmer AE; Ingelman-Sundberg M; Craig IW; Aitchison KJ
    J Psychopharmacol; 2012 Mar; 26(3):398-407. PubMed ID: 21926427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CYP2C19-Guided Escitalopram and Sertraline Dosing in Pediatric Patients: A Pharmacokinetic Modeling Study.
    Strawn JR; Poweleit EA; Ramsey LB
    J Child Adolesc Psychopharmacol; 2019 Jun; 29(5):340-347. PubMed ID: 30817183
    [No Abstract]   [Full Text] [Related]  

  • 3. Influence of
    Islam F; Magarbeh L; Elsheikh SSM; Kloiber S; Espinola CW; Bhat V; Frey BN; Milev R; Soares CN; Parikh SV; Placenza F; Hassel S; Taylor VH; Leri F; Blier P; Uher R; Farzan F; Lam RW; Turecki G; Foster JA; Rotzinger S; Kennedy SH; Müller DJ
    Can J Psychiatry; 2024 Mar; 69(3):183-195. PubMed ID: 37796764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2C19 and CYP2D6 and SSRIs.
    Brouwer JMJL; Nijenhuis M; Soree B; Guchelaar HJ; Swen JJ; van Schaik RHN; Weide JV; Rongen GAPJM; Buunk AM; de Boer-Veger NJ; Houwink EJF; van Westrhenen R; Wilffert B; Deneer VHM; Mulder H
    Eur J Hum Genet; 2022 Oct; 30(10):1114-1120. PubMed ID: 34782755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of age, weight, and CYP2C19 genotype on escitalopram exposure.
    Jin Y; Pollock BG; Frank E; Cassano GB; Rucci P; Müller DJ; Kennedy JL; Forgione RN; Kirshner M; Kepple G; Fagiolini A; Kupfer DJ; Bies RR
    J Clin Pharmacol; 2010 Jan; 50(1):62-72. PubMed ID: 19841156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Applications of CYP450 testing in the clinical setting.
    Samer CF; Lorenzini KI; Rollason V; Daali Y; Desmeules JA
    Mol Diagn Ther; 2013 Jun; 17(3):165-84. PubMed ID: 23588782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants.
    Bousman CA; Stevenson JM; Ramsey LB; Sangkuhl K; Hicks JK; Strawn JR; Singh AB; Ruaño G; Mueller DJ; Tsermpini EE; Brown JT; Bell GC; Leeder JS; Gaedigk A; Scott SA; Klein TE; Caudle KE; Bishop JR
    Clin Pharmacol Ther; 2023 Jul; 114(1):51-68. PubMed ID: 37032427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenetic Factors Influence Escitalopram Pharmacokinetics and Adverse Events in Youth with a Family History of Bipolar Disorder: A Preliminary Study.
    Honeycutt DC; Blom TJ; Ramsey LB; Strawn JR; Bruns KM; Welge JA; Patino LR; Singh MK; DelBello MP
    J Child Adolesc Psychopharmacol; 2024 Feb; 34(1):42-51. PubMed ID: 38377518
    [No Abstract]   [Full Text] [Related]  

  • 9. Escitalopram in Adolescents With Generalized Anxiety Disorder: A Double-Blind, Randomized, Placebo-Controlled Study.
    Strawn JR; Mills JA; Schroeder H; Mossman SA; Varney ST; Ramsey LB; Poweleit EA; Desta Z; Cecil K; DelBello MP
    J Clin Psychiatry; 2020 Aug; 81(5):. PubMed ID: 32857933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequencies of
    Scherf-Clavel M; Weber H; Unterecker S; Müller DJ; Deckert J
    World J Biol Psychiatry; 2024 Apr; 25(4):214-221. PubMed ID: 38493365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Age of onset for increased dose-adjusted serum concentrations of antidepressants and association with sex and genotype: An observational study of 34,777 individuals.
    Tveit K; Hermann M; Nilsen RM; Wallerstedt SM; Rongve A; Molden E; Hole K
    Eur J Clin Pharmacol; 2024 Mar; 80(3):435-444. PubMed ID: 38197945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of CYP2D6 Genotype on Paroxetine Serum Concentration.
    Hole K; Haslemo T; Molden E
    Ther Drug Monit; 2023 Oct; 45(5):683-688. PubMed ID: 37012633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of CYP2D6 and CYP2C19 metabolizer status with switching and discontinuing antidepressant drugs: an exploratory study.
    Brouwer JMJL; Wardenaar KJ; Nolte IM; Liemburg EJ; Bet PM; Snieder H; Mulder H; Cath DC; Penninx BWJH
    BMC Psychiatry; 2024 May; 24(1):394. PubMed ID: 38797832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of CYP2D6 and CYP2C19 genotypes on atomoxetine serum levels: A study based on therapeutic drug monitoring data.
    Smith RL; Molden E; Bernard JP
    Br J Clin Pharmacol; 2023 Jul; 89(7):2246-2253. PubMed ID: 36851891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenomic testing for CYP2C19 and CYP2D6 in cyclic vomiting syndrome.
    Patel M; Partovi O; Karrento K; Garacchi Z; Balasubramanian G; Venkatesan T
    Neurogastroenterol Motil; 2024 Jan; 36(1):e14705. PubMed ID: 37953495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Substantiation of a clopidogrel metabolism-associated gene (CYP2C19) variation among healthy individuals.
    Yadav AK; Chakkumkollath AK; Helna A; Birla S; Thimmulappa RK; Shambu SK; Vishwanath P; Prashant A
    Indian Heart J; 2023; 75(5):343-346. PubMed ID: 37217095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Physiologically Based Pharmacokinetic Modeling to Unravel the Drug-gene Interactions of Venlafaxine: Based on Activity Score-dependent Metabolism by CYP2D6 and CYP2C19 Polymorphisms.
    Shen C; Yang H; Shao W; Zheng L; Zhang W; Xie H; Jiang X; Wang L
    Pharm Res; 2024 Apr; 41(4):731-749. PubMed ID: 38443631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protocol for a pharmacogenetic study of antidepressants: characterization of drug-metabolizing profiles of cytochromes CYP2D6 and CYP2C19 in a Sardinian population of patients with major depressive disorder.
    Pinna M; Manchia M; Pisanu C; Pinna F; Paribello P; Carta A; Meloni A; Conversano C; Del Zompo M; Mola F; Squassina A; Carpiniello B
    Psychiatr Genet; 2021 Oct; 31(5):186-193. PubMed ID: 34282075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Relevance of Integrating CYP2C19 Phenoconversion Effects into Clinical Pharmacogenetics.
    Scherf-Clavel M; Weber H; Unterecker S; Frantz A; Eckert A; Reif A; Deckert J; Hahn M
    Pharmacopsychiatry; 2024 Mar; 57(2):69-77. PubMed ID: 38354747
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.